Physician profile
David B Casey
NPI 1447559604
$7,898.71
in general payments reported to CMS, 2019-2025
43 companies · $1,445 in 2025
The $1,445 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,997 · 2020: $452 · 2021: $630 · 2022: $1,334 · 2023: $1,145 · 2024: $896 · 2025: $1,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,387 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,386.99 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,018.75 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $783.04 | 2019-2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $692.68 | 2019-2024 | Xarelto |
| Cardiovascular Systems INC. | $523.69 | 2019 | |
| Abiomed | $425.98 | 2019-2025 | Impella |
| Medtronic, INC. | $377.92 | 2025 | Micra, Symplicity G3, Onyx Frontier |
| Novartis Pharmaceuticals Corporation | $348.17 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $348.16 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Pfizer INC. | $340.14 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $338.03 | 2019-2025 | Farxiga, Wainua |
| Boston Scientific Corporation | $307.78 | 2022-2025 | Avvigo Guidance System, Varithena Administration Pack, Watchman Access System |
| Kestra Medical Technology Services, INC. | $284.68 | 2022-2024 | Assure Wcd |
| Impulse Dynamics (USA) INC. | $222.16 | 2022-2023 | Optimizer |
| Bayer Healthcare Pharmaceuticals INC. | $207.51 | 2021-2024 | |
| Edwards Lifesciences Corporation | $205.48 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $192.10 | 2019-2025 | Repatha, Repatha |
| Heartflow, INC. | $163.11 | 2022-2025 | Ffrct |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.14 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $152.58 | 2022-2025 | Verquvo, Winrevair |
| Cvrx, INC. | $90.83 | 2024 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $78.84 | 2019-2024 | Camzyos |
| Astellas Pharma US INC | $77.00 | 2019 | |
| Esperion Therapeutics, INC. | $70.69 | 2023-2025 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $56.02 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $43.60 | 2023 | Arcalyst |
| Scpharmaceuticals INC. | $43.58 | 2024-2025 | |
| Novo Nordisk INC | $41.44 | 2025 | Wegovy |
| Lantheus Medical Imaging, INC. | $39.69 | 2023 | Definity |
| Portola Pharmaceuticals, LLC | $27.69 | 2019 | |
| Bridgebio Pharma, INC. | $23.25 | 2025 | Attruby |
| Irhythm Technologies, INC. | $22.87 | 2023 | Zio Xt Patch |
| Alnylam Pharmaceuticals INC. | $20.20 | 2025 | Amvuttra |
| Vital Connect, INC | $19.75 | 2023 | Vitalpatch Rtm |
| Lifenet Health | $19.71 | 2024 | Theragenesis Wound Matrix |
| Daiichi Sankyo INC. | $19.28 | 2023 | Injectafer |
| Lundbeck LLC | $17.32 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.31 | 2022 | |
| Amarin Pharma, INC. | $15.63 | 2019 | |
| Medtronic Vascular, INC. | $15.13 | 2020 | |
| Smith+Nephew, INC. | $13.99 | 2023 | Pico 7, Pico 14, Renasys Go V2 Home |
| Sanofi-Aventis U.S. LLC | $13.83 | 2021 | |
| Glaxosmithkline, LLC. | $13.51 | 2025 | Arexvy, Shingrix |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Casey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.